• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Outset Medical Appoints Karen Drexler to Board of Directors

    1/12/21 4:05:00 PM ET
    $OM
    $RMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $OM alert in real time by email

    SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bolstering its board of directors with the appointment of Karen Drexler. Drexler currently serves on the boards of ResMed (NYSE: RMD), a $31B data-driven sleep and respiratory market leader; VIDA Diagnostics, developer of AI-powered lung intelligence and imaging solutions; and Tivic Health, a bioelectronic medicine company. Named one of Women Inc. magazine’s most influential corporate directors in 2018, Drexler brings to Outset a deep understanding of how to utilize data analytics and machine learning to power the user experience, while supporting the patient at home and in the hospital setting.

    “Karen’s experience in the medtech field, using data analytics and a consumer-centric approach to creating a better patient experience, aligns beautifully with the commercial strategies we are implementing both in the home and the acute markets with Tablo,” said Outset Medical CEO Leslie Trigg. “She brings a new perspective and invaluable knowledge that will help fuel our rapid growth trajectory.”

    Drexler brings extensive technical and operational leadership to her role on the Outset board. Most recently, she was the CEO of Sandstone Diagnostics, a life science tools company focused on increased access to high-quality diagnostic testing. Prior to that, she founded and served as CEO at Amira Medical until its sale to Roche Diabetes Care. Drexler started her career at LifeScan where she managed a variety of functions and ultimately executed the sale of the company to Johnson & Johnson.

    “Over the course of my career I’ve worked with a variety of public and private medical device and diagnostics companies to find solutions for chronic disease management, all with the goal of creating better patient experiences and outcomes,” said Drexler. “From my very directly related experience working to improve life for people with diabetes, to looking at how AI can modernize clinical diagnostics and therapeutic solutions, I’m fascinated by companies that utilize technology to make patients’ lives better. Outset’s Tablo System reduces the burden of chronic kidney care for providers, patients and caregivers, showing how all stakeholders can win with the optimal use of technology and patient-centered designs.”

    Outset also announced today that TJ Carella, head of healthcare at Warburg Pincus, which first invested in the company more than 10 years ago, has stepped off the board.

    “TJ has been instrumental in supporting our efforts to scale the organization and achieve U.S. commercial success,” added Trigg. “His insights, and commitment to making an impact on the renal industry, helped us get to where we are today.”

    About Outset Medical

    Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

    Get the next $OM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OM
    $RMD

    CompanyDatePrice TargetRatingAnalyst
    ResMed Inc.
    $RMD
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    ResMed Inc.
    $RMD
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    ResMed Inc.
    $RMD
    3/19/2025$280.00Overweight
    Morgan Stanley
    ResMed Inc.
    $RMD
    3/19/2025Overweight
    Morgan Stanley
    ResMed Inc.
    $RMD
    1/16/2025Buy
    Goldman
    ResMed Inc.
    $RMD
    1/10/2025$252.00Neutral
    Piper Sandler
    ResMed Inc.
    $RMD
    12/13/2024$250.00Hold
    Stifel
    ResMed Inc.
    $RMD
    9/24/2024$280.00Outperform
    Robert W. Baird
    More analyst ratings

    $OM
    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

      Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4

      7/31/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Outset Medical Names First Chief Nursing Officer

      SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced Brittni McGill has been named to the newly created role of Chief Nursing Officer where she will apply her extensive nurse executive leadership experience to help increase strategic outreach and clinical program innovation designed to empower nurses and nurse leaders and elevate care. "Our entire Outset team understands and celebrates the critical role the nursing community and specifically, nurse executives, play in ensuring successful patient outcomes across

      7/30/25 9:01:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

      SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2025 after the close of trading on Wednesday, August 6, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on W

      7/16/25 4:03:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Farrell Michael J. sold $2,056,076 worth of ResMed Common Stock (8,009 units at $256.72) and exercised 8,009 units of ResMed Common Stock at a strike of $101.64 (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      7/9/25 8:37:55 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Director Farrell Peter C sold $241,438 worth of ResMed Common Stock (945 units at $255.49), decreasing direct ownership by 1% to 68,273 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      7/3/25 12:01:23 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Sandercock Brett exercised 2,883 units of ResMed Common Stock at a strike of $101.64 and sold $997,892 worth of ResMed Common Stock (3,883 units at $256.99), decreasing direct ownership by 1% to 84,283 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      7/2/25 5:53:52 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $OM
    $RMD
    SEC Filings

    See more
    • ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - RESMED INC (0000943819) (Filer)

      7/31/25 4:05:17 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Outset Medical Inc.

      SCHEDULE 13G - Outset Medical, Inc. (0001484612) (Subject)

      7/29/25 2:14:28 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by ResMed Inc.

      144 - RESMED INC (0000943819) (Subject)

      6/9/25 10:26:33 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $OM
    $RMD
    Financials

    Live finance-specific insights

    See more
    • Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

      Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4

      7/31/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Outset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

      SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2025 after the close of trading on Wednesday, August 6, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on W

      7/16/25 4:03:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

      SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location:https://investor.resmed.com •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Thursday, July 31, 2025, 9:30 p.m. BSTSydney, Friday, August 1, 2025, 6:30 a.m. AEST     Please note, Resmed

      7/1/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $OM
    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ResMed upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00

      7/16/25 7:50:57 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • ResMed upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00

      7/15/25 8:29:55 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on ResMed with a new price target

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight and set a new price target of $280.00

      3/19/25 10:13:23 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $OM
    $RMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

      SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

      5/14/25 9:00:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Resmed Names Salli Schwartz as Chief Investor Relations Officer

      SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

      4/21/25 5:00:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Jan De Witte joins GHO Capital as Operating Partner

      Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

      2/11/25 4:30:00 AM ET
      $IART
      $RMD
      Medical/Dental Instruments
      Health Care

    $OM
    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 4:53:46 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 4:26:01 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 10:32:13 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care